Results 81 to 90 of about 43,858 (197)

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Elevated IL‐4 and IL‐13 Expression in Hailey‐Hailey Disease: Evidence for Th2‐Mediated Pathogenesis and Targeted Treatment

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Hailey‐Hailey disease (HHD) is a rare autosomal dominant blistering disorder caused by mutations in the ATP2C1 gene, which impair keratinocyte adhesion through disrupted calcium signaling. While traditionally considered a structural defect, recent studies suggest that Th2‐mediated inflammation may exacerbate disease pathology ...
Simonetta I. Gaumond, Victoria Soto, Beatriz Abdo Abujamra, Franco Rongioletti, John A. McGrath, Ivan Jozic, Paolo Romanelli   +6 more
wiley   +1 more source

Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study

RMD Open
Objectives Compare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib versus tumour necrosis factor inhibitors (TNFi) in Oral ...
Arne Yndestad, Maya H Buch, Carol A Connell, Kenneth Kwok, Ted Mikuls, Deepak L Bhatt, Jon T Giles, Christina Charles-Schoeman, Gary G Koch, Edward Nagy, Steven Ytterberg, Hyejin Jo, Karim Richard Masri   +12 more
doaj   +1 more source

Cold plasma treatment for oral lichen planus: a retrospective case collection and proposal of a new clinical score

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Oral lichen planus (OLP) is a chronic autoimmune mucosal disease with malignant potential and limited treatment options. This study evaluated the long‐term efficacy and safety of cold atmospheric plasma (CAP) therapy in therapy‐refractory OLP and introduced the novel Lichen Planus Severity Score (LPSS).
Christian Seebauer, Hans‐Robert Metelmann, Mohamed Falougy, Wolfram Kaduk, Lasse Kremer, Georg Daeschlein   +5 more
wiley   +1 more source

Epidemiology, Diagnosis and Management of Alopecia Areata: An Asia‐Pacific Modified Delphi Expert Panel Recommendations

International Journal of Dermatology, EarlyView.
A panel of 18 dermatologists participated in a three‐round Delphi‐based consensus process to generate a standardized framework for the diagnosis and management of alopecia areata (AA) in Asia Pacific. Recommendations focus on practicality and clinical relevance within the regional context.
Rodney Sinclair, Chao‐Chun Yang, Wen‐Hung Chung, Rachita Dhurat, Anil Ganjoo, Saranya Khunkhet, Jinran Lin, Anchala Parthasaradhi, Hyun‐Tae Shin, Kihyuk Shin, Poonkiat Suchonwanit, Kian Teo Tan, Jyh Jong Tang, Wenyu Wu, Felix Boon‐Bin Yap, Leona Yip, Angeline Yong, Cheng Zhou   +17 more
wiley   +1 more source

Assessments of CYP‐Inhibition‐Based Drug–Drug Interactions Between Tofacitinib and Lipid‐Lowering Agents in Rats Both In Vitro and In Vivo

Pharmacology Research & Perspectives
Tofacitinib is a widely used medication for the treatment of arthritis. It has been reported that some patients experience abnormal cholesterol levels following treatment, leading to recommendations for the coadministration of lipid‐lowering drugs such ...
Hang Yang, Shuanghu Wang, Quan Zhou, Peiwu Geng, Zebei Lu, Qinrong Lin, Chunhong Chen, Yunfang Zhou, Jianping Cai, Dapeng Dai   +9 more
doaj   +1 more source

Evaluation of Discontinuation and Re‐Initiation of Biologic Therapies in Psoriasis: Real‐World Data

International Journal of Dermatology, EarlyView.
The cumulative probability of remaining relapse‐free following biologic therapy discontinuation was 35.6%, 19%, 11.6%, and 9.1% at 6, 12, 18, and 24 months, respectively. Prolonged relapse durations were associated with a low baseline PASI score, the presence of a PASI 90 response at discontinuation, the absence of triggering factors, and the use of IL‐
Ahmet Taha Aydemir, Nihal Kundakcı
wiley   +1 more source

Swiss Practice Recommendations for Chronic Prurigo Including Prurigo Nodularis

International Journal of Dermatology, EarlyView.
Chronic prurigo, including prurigo nodularis, is a chronic, often treatment‐refractory condition characterized by persistent pruritus and chronic scratch lesions. Advances in the understanding of its underlying pathophysiology have enabled the development of novel targeted therapies; however, management remains challenging due to the expanding range of
Simon M. Mueller, Helmut Beltraminelli, Wolf‐Henning Boehncke, Maximilian Böhm, Antonio Cozzio, Peter Häusermann, Ahmad Jalili, Antonios G. A. Kolios, Claudia Lang, Eva Loos, Christoph Schlapbach, Curdin Conrad   +11 more
wiley   +1 more source

Genetic Risk Meets the Intestinal Barrier

Immunology &Cell Biology, EarlyView.
Top: At increasing cellular resolution, the Alegbe et al. report that expression quantitative trait loci (eQTLs) are enriched in enhancer regions rather than promoters. They speculate that enhancer eQTLs only come into effect during certain cellular contexts, making them more tolerable. Bottom: Alegbe et al.
J. L. E. Tearle, K. R. James
wiley   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source